RTRX

New name reflects dedication to patient-inspired mission of identifying, developing and delivering life-changing rare disease therapies Company’s shares to trade under new ticker symbol TVTX on November 19 SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Retrophin Inc., (NASDAQ: RTRX) today announced that the Company has changed its global corporate name to Travere Therapeutics, Inc. This new name reflects the Company’s steadfast dedication to helping people as they navigate life with rare disease, as well as the forward momentum of its promising pipeline of potential first-in-class therapeutic candidates. In conjunction with the name change, the Company expects to begin trading under the ne

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the completion of its previously announced acquisition of Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58 for the treatment of classical homocystinuria (HCU). OT-58 is a novel investigational human enzyme replacement therapy being evaluated in Phase 1/2 development for the treatment of classical HCU, a rare metabolic disorder characterized by elevated levels of plasma homocysteine that can lead to life-threatening thrombotic events such as stroke and heart attacks, ophthalmologic and skeletal complications,

SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming virtual investor conferences in November and December: Jefferies 2020 Virtual London Healthcare ConferenceDate: Wednesday, November 18, 2020Time: 6:45 p.m. GMT (1:45 p.m. ET) 2020 Evercore ISI Virtual HealthCONx ConferenceDate: Tuesday, December 1, 2020Time: 1:25 p.m. ET Live webcasts will be available at http://ir.retrophin.com/events and archived replays will be accessible for up to 30 days. About Retrophin Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to pe

Pivotal DUPLEX Study of sparsentan in FSGS nears completion of enrollment; topline proteinuria data expected 1Q21 Pivotal PROTECT Study achieved enrollment of 280th patient with IgAN to enable topline proteinuria data in 3Q21 Expanding pipeline of potential first-in-class therapies with agreement to acquire OT-58 for the treatment of classical homocystinuria Net product sales increased 15 percent to $51 million in the third quarter SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today reported its third quarter 2020 financial results and provided a corporate update. Patient enrollment nears completion in the Phase 3 DUPLEX Study evaluat

Agreement adds OT-58, a novel enzyme replacement therapy in Phase 1/2 development for the treatment of classical homocystinuria Compelling strategic fit that will expand pipeline of potential first-in-class therapies targeting rare diseases Retrophin to host conference call and webcast today at 5:00 p.m. ET SAN DIEGO, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it has entered into a definitive agreement to acquire Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58 for the treatment of classical homocystinuria (HCU). OT-58 is a novel investigational enzyme

SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal segmental glomerulosclerosis (FSGS) that achieved complete remission of proteinuria in the Phase 2 DUET Study, at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined. The Company and its collaborators will also feature encore presentations of preclinical data supporting the potential for sparsentan to protect kidney function in additional rare glomerular diseases. ASN Kidney Week 2020 Reimagined is being held virtually October 19–25, 2020. Oral Presentation: Complete Remissio